Back

Disease progression among patients receiving tafamidis for transthyretin amyloidosis with cardiomyopathy in a real-world setting

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Ambulatory care and monitoring in heart failure Treatment HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Daniel Judge

Medical University of South Carolina, Charleston (United States of America)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics of patients with malnutrition or at risk of malnutrition and heart failure identified in the outpatient setting
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video
Presentation thumbnail
Trends in care for ambulatory patients with heart failure at a large tertiary centre in England
Doctor H. Ismail (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Effect of Cardiomems telemonitoring system on outcomes in patients with heart failure outside clinical trials: a systematic review and meta-analysis
Doctor C. Kapelios (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Gender differences in efficiency of the telemedicine care of heart failure patients.Tthe results from the TeleEducare-HF study
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Targeted plasma profiling of the proteomic response to physical activity in heart failure with preserved ejection fraction
Ms A. Kerber (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ambulatory care and monitoring in heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
thumbnail
Congress Presentation
Exploring tafamidis outcomes across varying disease severities in ATTR-CM
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources